Original Investigation
MAIN OUTCOMES AND MEASURES The primary outcome was fatal or nonfatal acute
myocardial infarction occurring within 30 days of ED presentation, adjudicated with serial
troponin testing. The secondary outcome was the proportion of patients potentially suitable
for early discharge at each cutoff concentration.
RESULTS Of the 3155 eligible patients, 1771 were male (56.1%), and mean (SD) age was 57.4
(13.3) years. Acute myocardial infarction developed in 291 individuals (9.2%). The 1.2-ng/L
limit of detection gave a sensitivity of 99.0% (95% CI, 96.8%-99.7%) and an NPV of 99.5%
(95% CI, 98.4%-99.9%). This cutoff level would allow for early discharge of 594 patients
(18.8%). All higher rounded cutoff values had sensitivities less than 98.0%. Diagnostic
performance of the limit of detection was maintained when patients were stratified by age,
sex, risk factors, presence of coronary artery disease, and early presentation.
(Reprinted) 405
P
atients with suspected cardiac chest pain account for
more than 6 million emergency department (ED) vis- Key Points
its annually across the United States.1 Current Ameri-
Question What is the diagnostic performance of low
can Heart Association guidelines2 recommend serial measure- concentrations of high-sensitivity troponin I (hs-cTnI) on
ments of contemporary cardiac troponin at presentation and presentation to the emergency department?
3 to 6 hours after symptom onset. As a result, most patients
Findings Pooled analysis of patients from prospectively recruited
require prolonged assessment prior to safe discharge. This di-
emergency department cohort studies demonstrated that the
agnostic approach leads to a large number of costly, poten- limit of detection has a high sensitivity and negative predictive
tially avoidable hospital admissions.1,3 Strategies that could value for acute myocardial infarction, potentially allowing for early
safely identify a large proportion of patients suitable for dis- discharge of some patients. Higher rounded cutoff values had
charge after a single sample of blood is taken on arrival in the lower sensitivities.
ED would have major benefits to health care systems. Meaning In patients with symptoms suggestive of cardiac
Low concentrations of high-sensitivity cardiac troponin ischemia, the limit of detection of hs-cTnI may have the required
(hs-cTn) assays determined at presentation to the ED in com- diagnostic performance for clinical implementation, whereas
bination with nonischemic electrocardiogram (ECG) findings rounded cutoff values above this cutoff level do not.
demonstrate excellent prognostic ability in patients with sus-
pected acute coronary syndromes.4,5 It has therefore been
suggested5 that the clinical application of strategies that use
these low cutoff values could transform the assessment of chest chester, England, in the Novel Biomarkers of Acute Coronary
pain by identifying a large proportion of patients at low risk Syndromes With Metabolomics Study.10 The final cohort was
for myocardial infarction (MI). These patients may be suit- enrolled at Stockport National Health Service Trust, Stock-
able for immediate discharge after a single sample of blood is port, England, in the Validation of the Manchester Acute
taken on arrival. However, large-scale cohort studies4,5 that re- Coronary Syndromes decision rule study.11
ported excellent negative predictive values (NPVs) (>99%) using Written informed consent was obtained from all patients,
very low or undetectable cutoff strategies have not openly re- and the study protocol was approved by the respective local
ported the more important measure of diagnostic perfor- ethics committees (Human Research Ethics Committee,
mance: sensitivity. As practitioners may intuitively interpret Royal Brisbane and Women's Hospital [Australia], Upper
low cutoff hs-cTn strategies as diagnosticrather than prog- South A Regional Ethics Committee [New Zealand], Frenchay
nostictools, the provision of sensitivity values for informed Research Ethics Committee [Poole], and North West Cheshire
decision making in exclusion of acute coronary syndromes is Research Ethics Committee [Manchester and Stockport]).
critical. In a meta-analysis6 of the diagnostic performance of The present analysis, with waiver of informed consent and
undetectable hs-cTnT levels in which sensitivity was pro- use of deidentified data, was approved by those same ethics
vided, the point estimate was 97.4% (95% CI, 94.9%-98.7%). committees. Recruitment was undertaken from November 1,
This finding is below the minimum clinically acceptable thresh- 2007, to August 10, 2013.
old of 99.0%.7 All patients recruited in the trials were eligible for enroll-
We aimed to evaluate the diagnostic performance of low ment if they presented with symptoms suggestive of cardiac
concentrations of hs-cTnI in patients with suspected cardiac ischemia (acute chest, epigastric, neck, jaw, or arm pain, or dis-
chest pain and a nonischemic ECG from 5 international ED co- comfort or pressure without an apparent noncardiac source).
horts of prospectively recruited patients. We specifically in- For all cohorts, patients were excluded if any of the following
tended to report sensitivity for the diagnosis of fatal or non- were present: ST-segment elevation MI or new left bundle-
fatal acute MI (AMI). branch block, new-onset ECG changes diagnostic of ischemia
(ST-segment depression 1 mm or T-wave inversion consis-
tent with ischemia), significant arrhythmias (sustained supra-
ventricular tachycardia, second-degree or complete heart
Methods block, or sustained or recurrent ventricular arrhythmias), age
Study Design and Participants younger than 18 years, a clear cause of the symptoms other than
The study population consisted of eligible patients recruited acute coronary syndromes, pregnancy, inappropriate recruit-
into 5 prospective ED cohort studies. The first 2 cohorts were ment (eg, terminal illness), unwillingness to consent, and if fol-
enrolled at 2 tertiary teaching hospitals (Royal Brisbane and low-up was considered impossible. Specific to the present
Womens Hospital, Brisbane, Australia, and Christchurch analysis, participants in whom hs-cTnI assay results deter-
Hospital, Christchurch, New Zealand) in the ADAPT (2-Hour mined on presentation to the ED were not available were
Accelerated Diagnostic Protocol to Assess Patients With Chest excluded. We selected patients in whom new-onset ECG
Pain Symptoms Using Contemporary Troponins as the Only changes diagnostic of ischemia were absent to maximize clini-
Biomarker) study.8 The third cohort was enrolled at Poole cal applicability of the results and reflect clinical practice in
Hospital National Health Service Trust, Dorset, England, in which patients with ECG changes are immediately defined as
the TRUST (Triage Rule-Out Using High-Sensitivity Troponin) high risk and therefore not suitable for discharge. All ECG
study.9 The fourth cohort was enrolled at Central Manchester findings were adjudicated by blinded research staff (E.C., S.C.,
University Hospitals National Health Service Trust, Man- C.H., W.P., and K.G.).
All participants had laboratory troponin concentrations possible to evaluate the outcome separately using this assay.
measured at presentation and at least 6 hours after presenta- The end point was adjudicated by researchers (E.C., R.B., S.C.,
tion (Brisbane, Christchurch, and Poole) or at least 12 hours af- C.H., W.P., and K.G.) blinded to the presentation hs-cTnI re-
ter the development of peak symptoms (Manchester and Stock- sults but with the knowledge of local troponin assay results.
port) as part of clinical care. Electrocardiograms were recorded
on presentation. Treatment was managed according to local Statistical Analysis
protocols. All clinical management, including the decision to Baseline characteristics of the study population were ana-
perform stress testing or coronary angiography, was at the dis- lyzed with conventional group descriptive statistics accord-
cretion of the attending physician. ing to study cohort. Results were pooled for calculation of sen-
Patient data were recorded according to standardized data sitivity, specificity, NPV, and positive predictive value. To
collection forms using a published data dictionary.12 Fol- illustrate the validity of each cutoff value as an exclusion tool,
low-up events were monitored by dedicated research staff a minimum clinically acceptable sensitivity threshold of 99%
through a combination of telephone contact, corroboration by was chosen, below which the missed-event rate becomes un-
review of hospital online patient management systems, and acceptable to practitioners.7 Subgroup analysis for age, sex, car-
query to the national death registries at least 12 months after diac risk factor burden, history of coronary artery disease, and
index presentation. time from symptom onset to ED presentation was under-
Research samples obtained on presentation were centri- taken for the lower limit of detection cutoff concentration (1.2
fuged, and serum was stored frozen at 70C or below for later ng/L). Data were analyzed using Stata, version 12 (StataCorp).
analysis in a blinded fashion using an hs-cTnI assay (Archi-
tect Stat; Abbott Diagnostics) with a lower limit of detection
of 1.2 ng/L (to convert to nanograms per milliliter, divide by
1000; micrograms per liter, multiply by 106) (range, 1.2-1.9
Results
ng/L) and a 10% coefficient of variation of 4.7 ng/L. Samples Data were available for 3155 patients across 5 cohorts, includ-
were thawed, mixed, and centrifuged for 30 minutes at 3000g ing 1164 (36.9%) from Australia, 810 (25.7%) from New Zea-
and 4C for serum samples or twice for 10 minutes at 3000g land, and 1181 (37.4%) from the United Kingdom (867 from
for plasma samples before analysis and according to the manu- Poole, 134 from Manchester, and 180 from Stockport). Of these,
facturers instructions. Long-term stability of hs-cTnI has been 1771 (56.1%) individuals were male and the mean (SD) age was
demonstrated.13 57.4 (13.3) years. From the original cohorts, 626 patients were
We determined a priori that primary cutoff concentra- excluded owing to the unavailability of hs-cTnI results; these
tions for analysis were the lower limit of detection of the patients were not included in the 3155 individuals in the pres-
hs-cTnI assay (1.2 ng/L) and rounded cutoff concentrations ent analysis.
below 5 ng/L, the threshold previously identified5 as allow- Baseline characteristics of the study population, classi-
ing the maximal number of patients for potential discharge fied according to recruiting center, are summarized in the Table.
with an NPV of greater than 99.5%. The analysis of rounded Of the 3155 patients included in the analysis, 291 developed a
concentrations was done because it is common practice for fatal or nonfatal AMI within 30 days of the index presenta-
clinical laboratories to round hs-cTnI results before reporting tion, resulting in a prevalence of 9.2%, ranging from 3.4% (Aus-
them. Rounding occurred up or down to the nearest whole tralia) to 18.1% (New Zealand). Patients from New Zealand were
number (eg, from 2.2 to 2 ng/L and from 2.6 to 3 ng/L). significantly older, had a higher cardiac risk factor burden (with
the exception of smoking), and were more likely to have a his-
Outcomes tory of cardiac disease compared with the cohort with the low-
The primary outcome was the presence of fatal or nonfatal AMI est prevalence of AMI (Australia) (P < .05 for all). Of the 291 pa-
occurring within 30 days of hospital attendance (including the tients adjudicated as having an AMI, 277 (95.2%) individuals
index ED visit). The secondary outcome was the proportion received the diagnosis at the index presentation and 14 (4.8%)
of patients potentially suitable for early discharge at each cut- were identified during the following 30 days. Calculation of
off concentration. diagnostic performance using 2 2 tables is available in eTable
The presence of AMI was defined according to the third uni- 2 in the Supplement.
versal definition of MI,14 which states that a rise and/or fall in
troponin, with at least 1 value above the 99th centile value in Diagnostic Accuracy of the Limit of Detection
the context of a patient with ischemic symptoms or signs (ECG of hs-cTnI With Nonischemic ECG
changes, such as new significant ST-segment T-wave changes Troponin concentrations were below the lower limit of detec-
and pathologic Q waves, or imaging evidence, such as new re- tion (1.2 ng/L) in 594 (18.8%) of 3155 patients. This cutoff, to-
gional wall motion abnormality or intracoronary thrombus by gether with a nonischemic ECG, would allow up to 18.8% of
angiography) would satisfy the diagnosis. The diagnosis of AMI patients to be discharged with a sensitivity of 99.0% (95% CI,
was adjudicated using presentation and late troponin results, 96.8%-99.7%) and an NPV of 99.5% (95% CI, 98.4%-99.9%)
according to assays in use at each institution at the time of re- (Figure 1A and B and eTable 3 in the Supplement). None of the
cruitment (eTable 1 in the Supplement). Blood samples ob- 3 (0.5%) patients with false-negative results died within 30 days
tained 6 to 12 hours after patient presentation for clinical man- of presentation. eTable 4 in the Supplement summarizes the
agement were not available for hs-cTnI; therefore, it was not clinical characteristics of patients with a presentation hs-cTnI
below the lower limit of detection and nonischemic ECG with low each cutoff concentration and the cumulative missed-
a diagnosis of fatal or nonfatal AMI. All 3 patients were men event rate are shown in Figure 2.
and from a cohort (Poole) in which outcomes were adjudi-
cated using an alternative high-sensitivity troponin assay (Elec- Stratified Subgroup Analysis at the Lower Limit of Detection
sys hs-cTnT; Roche Diagnostics). At the upper limit of detec- The sensitivity of an hs-cTnI concentration less than 1.2 ng/L
tion for the hs-cTnI assay (<2 ng/L), 807 (25.6%) patients would for AMI was similar in men and women and when stratified
have been eligible for early discharge but with a sensitivity of by age, cardiac risk factor burden, and history of coronary ar-
97.9% (95% CI, 95.4%-99.2%) and NPV of 99.3% (95% CI, tery disease (Figure 3 and eTable 5 in the Supplement). No pa-
98.3%-99.7%). tient aged 80 years or older (187 [5.9%]) had a presentation
hs-cTnI concentration below 1.2 ng/L. In a cohort with docu-
Diagnostic Accuracy of Rounded Low Cutoff Concentrations mented time from symptom onset to ED presentation, 1047
With Nonischemic ECG of 3124 patients (33.5%) were classified as early presenters (time
The sensitivity decreased with increasing cutoff concentra- from symptom onset to ED presentation 2 hours). In these
tions (Figure 1A and eTable 3 in the Supplement). All rounded patients, test sensitivity for AMI at 1.2 ng/L was maintained
cutoff values above 1.2 ng/L, up to and including 5 ng/L, had at 98.6% (95% CI, 91.8%-99.9%) (Figure 3 and eTable 5 in the
sensitivities less than 98% (albeit with NPVs >99%). The cut- Supplement). The reduction in diagnostic performance of
off concentration of 5 ng/L had an excellent NPV (99.2% [95% hs-cTnI cutoff concentrations above 1.2 ng/L to exclude AMI
CI, 98.8%-99.5%]) but poor sensitivity (94.5% [95% CI, 91.1%- cutoff was more marked in early presenters (eFigure in the
96.7%]). The proportion of patients with an hs-cTnI value be- Supplement).
Figure 1. Diagnostic Accuracy of the Limit of Detection and Rounded Low Cutoff Concentrations
of High-Sensitivity Troponin I (hs-cTnI) With Nonischemic Electrocardiogram
100 100
95 80
Sensitivity, %
Specificity, %
90 60
85 40
80 Sensitivity 20
Specificity
75 0
<1.2 2 3 4 5 6 7 8 9 10 11 12 13 14
hs-cTnl Concentration at Presentation, ng/L
Figure 2. Proportion of Patients With a High-Sensitivity Troponin I (hs-cTnI) Concentration Below Each Cutoff
Concentration and the Cumulative Missed Event Rate
80
70
60
No., %
50
40
30
20
10
0
<1.2 2 3 4 5 6 7 8 9 10 11 12 13 14
hs-cTnl Concentration at Presentation, ng/L 1.2 ng/L represents the lower limit of
detection.
Our findings can be applied only to the assay tested compared with those of prior studies. 4,5,15-17 Finally, no
(hs-cTnI) and cannot be translated to other assays, even patient was discharged according to presentation hs-cTnI
high-sensitivity ones. The hs-cTnI assay is recommended assay results and the proportion of patients undergoing fur-
for clinical use as a high-sensitivity assay by consensus ther cardiac testing was high across all cohorts (Table).
guidelines.18 However, physicians should be aware that, at Therefore, whether the strategies tested can be successfully
low concentrations, test results are less reliable than at the implemented into clinical practice and what further testing is
99th percentile19; therefore, any clinical implementation required remains unknown. The choice of outcome measure
should be a multidisciplinary decision between ED physi- for this analysis (fatal or nonfatal AMI occurring within 30
cians, cardiologists, and laboratory staff. No hs-cTn assay days) fails to incorporate the full spectrum of acute coronary
is currently approved for use by the US Food and Drug syndromes (eg, patients who may require urgent revascular-
Administration, and whether the use of low concentrations ization). Therefore, a key concept in ensuring the safety of
of hs-cTn in clinical practice will be approved remains this biomarker strategy is the availability of timely outpatient
unknown. testing to ensure early detection of such patients. Further
Our analysis has several limitations. First, outcomes were studies are required (ideally a randomized clinical trial) to
adjudicated using troponin assays, both sensitive and high- determine the clinical effectiveness of low cutoff concentra-
sensitivity, in clinical use at the time of patient recruitment tions of high-sensitivity troponin.
rather than the hs-cTnI assay under evaluation. This
approach may lead to misclassification bias. Second, many
patients were excluded from the original cohorts as a result
of the unavailability of hs-cTnI results. This exclusion may
Conclusions
result in selection bias. Third, we selected patients in whom High-sensitivity troponin I concentrations determined at pre-
new-onset ECG changes diagnostic of ischemia were absent sentation to the ED that were below the limit of detection iden-
to reflect clinical practice. This method may serve to reduce tified 18.8% of patients potentially suitable for discharge with
the outcome prevalence in the cohort as a whole and there- a high sensitivity for AMI. Rounded cutoff values above the
fore raise the NPV of the index test. Furthermore, the popula- limit of detection may not have the required sensitivity for clini-
tion selected for this analysis was likely to be of lower risk cal implementation.
ARTICLE INFORMATION Carley, Greaves. Hospira, and Aventis. Dr Greaves has received
Accepted for Publication: April 8, 2016. Critical revision of the manuscript for important funding from AstraZeneca for related research. No
intellectual content: All authors. other disclosures were reported.
Published Online: June 1, 2016. Statistical analysis: Carlton, Greenslade, Body,
doi:10.1001/jamacardio.2016.1309. Funding/Support: Australia/New Zealand cohorts:
Carley, Lord. Funding for the ADAPT study was predominantly
Open Access: This article is published under the Obtained funding: Carlton, Greenslade, Cullen, provided by the Christchurch Heart Institute and
JAMA Cardiology open access model and is free to Than, Greaves. the Queensland Emergency Medicine Research
read on the day of publication. Administrative, technical, or material support: Foundation with a small (20%) contribution from
Author Affiliations: Emergency Department, Kendall, Greaves. industry (Abbott and Alere). Poole, England,
Southmead Hospital, North Bristol National Health Study supervision: Cullen, Than, Aldous, Greaves. cohort: Funding was provided by the Royal College
Service Trust, Bristol, England (Carlton, Kendall); Conflict of Interest Disclosures: All authors have of Emergency Medicine of the United Kingdom,
Emergency Medicine, Royal Brisbane and Womens completed and submitted the ICMJE Form for Bournemouth University. Manchester, England,
Hospital, Brisbane, Australia (Greenslade, Cullen, Disclosure of Potential Conflicts of Interest. Dr cohort: Funding was received from the Royal
Hammett, Parsonage); School of Medicine, The Carlton has undertaken research under College of Emergency Medicine of the United
University of Queensland, Brisbane, Australia collaborative agreements with Abbott and Randox Kingdom, as well as fellowship funding from the
(Greenslade, Cullen); School of Public Health, Laboratories. Dr Cullen has received funding from United Kingdom National Institute for Health
Queensland University of Technology, Brisbane, Abbott, Roche, Alere, Siemens, and Radiometer Research (NIHR) and by the NIHR Clinical Research
Australia (Greenslade, Cullen); Central Manchester Pacific for clinical trials and from Alere, Boehringer Network (UK CRN 8376). Stockport, England,
University Hospitals, National Health Service Ingelheim, Pfizer, AstraZeneca, Abbott, Novartis, cohort: Funding was received from the Royal
Foundation Trust, Manchester, England (Body, and Radiometer Pacific for speaking and education. College of Emergency Medicine of the United
Carley, Keevil); Department of Emergency Dr Body has undertaken research under Kingdom as well as fellowship funding from the
Medicine, Christchurch Hospital, Christchurch, collaborative agreements with Roche, Siemens NIHR and by the NIHR Clinical Research Network
New Zealand (Than, Pickering, Aldous); Diagnostics, Alere, and Randox Laboratories and (UK CRN 8376).
Department of Medicine, University of Otago, has accepted travel and accommodation for Role of the Funder/Sponsor: For all cohorts, no
Christchurch, New Zealand (Pickering); School of conferences from Roche Diagnostics and Randox commercial organization or sponsor was involved in
Medicine, The University of Notre Dame, Sydney, Laboratories. Dr Than has received funding from the design and conduct of the study; collection,
Australia (Lord); Sunshine Coast Hospital and Alere, Abbott, Beckman, and Roche for speaking management, analysis and interpretation of the
Health Services, University of the Sunshine Coast, and support for other research. Dr Aldous received data; and preparation, review or approval of the
Nambour, Australia (Greaves). funding from the National Heart Foundation (New manuscript; and decision to submit the manuscript
Author Contributions: Dr Carlton had full access to Zealand) for cardiac research. Dr Kendall has for publication.
all the data in the study and takes responsibility for received funding from Boehringer Ingelheim and
Novartis for speaking, education, and support for Additional Contributions: We are indebted to the
the integrity of the data and the accuracy of the patients who participated in the study. We thank
data analysis. other research. Dr Parsonage received funding from
the Queensland Emergency Medicine Research the research staff, emergency department staff,
Study concept and design: Carlton, Cullen, Body, and laboratory technicians of all participating
Aldous, Lord, Greaves. Foundation, Abbott Diagnostics, Roche, Alere, and
Beckmann Coulter for research. He also has facilities for their valuable efforts.
Acquisition, analysis, or interpretation of data: All
authors. received honoraria, travel expenses, and
Drafting of the manuscript: Carlton, Than, Pickering, consultancy fees from Abbott, AstraZeneca,